Identification of novel methylation markers in hepatocellular carcinoma using a methylation array

So Hyun Shin, Baek-Hui Kim, Ja June Jang, Kyung Suk Suh, Gyeong Hoon Kang

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Promoter CpG island hypermethylation has become recognized as an important mechanism for inactivating tumor suppressor genes or tumor-related genes in human cancers of various tissues. Gene inactivation in association with promoter CpG island hypermethylation has been reported to be four times more frequent than genetic changes in human colorectal cancers. Hepatocellular carcinoma is also one of the human cancer types in which aberrant promoter CpG island hypermethylation is frequently found. However, the number of genes identified to date as hypermethylated for hepatocellular carcinoma (HCC) is fewer than that for colorectal cancer or gastric cancer, which can be attributed to fewer attempts to perform genome-wide methylation profiling for HCC. In the present study, we used bead-array technology and coupled methylation-specific PCR to identify new genes showing cancer-specific methylation in HCC. Twenty-four new genes have been identified as hypermethylated at their promoter CpG island loci in a cancer-specific manner. Of these, TNFRSF10C, HOXA9, NPY, and IRF5 were frequently hypermethylated in hepatocellular carcinoma tissue samples and their methylation was found to be closely associated with inactivation of gene expression. Further study will be required to elucidate the clinicopathological implications of these newly found DNA methylation markers in hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)1152-1159
Number of pages8
JournalJournal of Korean Medical Science
Volume25
Issue number8
DOIs
Publication statusPublished - 2010 Aug 1

Fingerprint

Methylation
Hepatocellular Carcinoma
CpG Islands
Stomach Neoplasms
Colorectal Neoplasms
Neoplasms
Genes
Neoplasm Genes
Gene Silencing
DNA Methylation
Tumor Suppressor Genes
Genetic Markers
Genome
Technology
Gene Expression
Polymerase Chain Reaction

Keywords

  • Bead array
  • Carcinoma
  • CpG Islands
  • DNA methylation
  • Hepatocellular

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. / Shin, So Hyun; Kim, Baek-Hui; Jang, Ja June; Suh, Kyung Suk; Kang, Gyeong Hoon.

In: Journal of Korean Medical Science, Vol. 25, No. 8, 01.08.2010, p. 1152-1159.

Research output: Contribution to journalArticle

Shin, So Hyun ; Kim, Baek-Hui ; Jang, Ja June ; Suh, Kyung Suk ; Kang, Gyeong Hoon. / Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. In: Journal of Korean Medical Science. 2010 ; Vol. 25, No. 8. pp. 1152-1159.
@article{b400663146924820aaf896f0eec37197,
title = "Identification of novel methylation markers in hepatocellular carcinoma using a methylation array",
abstract = "Promoter CpG island hypermethylation has become recognized as an important mechanism for inactivating tumor suppressor genes or tumor-related genes in human cancers of various tissues. Gene inactivation in association with promoter CpG island hypermethylation has been reported to be four times more frequent than genetic changes in human colorectal cancers. Hepatocellular carcinoma is also one of the human cancer types in which aberrant promoter CpG island hypermethylation is frequently found. However, the number of genes identified to date as hypermethylated for hepatocellular carcinoma (HCC) is fewer than that for colorectal cancer or gastric cancer, which can be attributed to fewer attempts to perform genome-wide methylation profiling for HCC. In the present study, we used bead-array technology and coupled methylation-specific PCR to identify new genes showing cancer-specific methylation in HCC. Twenty-four new genes have been identified as hypermethylated at their promoter CpG island loci in a cancer-specific manner. Of these, TNFRSF10C, HOXA9, NPY, and IRF5 were frequently hypermethylated in hepatocellular carcinoma tissue samples and their methylation was found to be closely associated with inactivation of gene expression. Further study will be required to elucidate the clinicopathological implications of these newly found DNA methylation markers in hepatocellular carcinoma.",
keywords = "Bead array, Carcinoma, CpG Islands, DNA methylation, Hepatocellular",
author = "Shin, {So Hyun} and Baek-Hui Kim and Jang, {Ja June} and Suh, {Kyung Suk} and Kang, {Gyeong Hoon}",
year = "2010",
month = "8",
day = "1",
doi = "10.3346/jkms.2010.25.8.1152",
language = "English",
volume = "25",
pages = "1152--1159",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "8",

}

TY - JOUR

T1 - Identification of novel methylation markers in hepatocellular carcinoma using a methylation array

AU - Shin, So Hyun

AU - Kim, Baek-Hui

AU - Jang, Ja June

AU - Suh, Kyung Suk

AU - Kang, Gyeong Hoon

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Promoter CpG island hypermethylation has become recognized as an important mechanism for inactivating tumor suppressor genes or tumor-related genes in human cancers of various tissues. Gene inactivation in association with promoter CpG island hypermethylation has been reported to be four times more frequent than genetic changes in human colorectal cancers. Hepatocellular carcinoma is also one of the human cancer types in which aberrant promoter CpG island hypermethylation is frequently found. However, the number of genes identified to date as hypermethylated for hepatocellular carcinoma (HCC) is fewer than that for colorectal cancer or gastric cancer, which can be attributed to fewer attempts to perform genome-wide methylation profiling for HCC. In the present study, we used bead-array technology and coupled methylation-specific PCR to identify new genes showing cancer-specific methylation in HCC. Twenty-four new genes have been identified as hypermethylated at their promoter CpG island loci in a cancer-specific manner. Of these, TNFRSF10C, HOXA9, NPY, and IRF5 were frequently hypermethylated in hepatocellular carcinoma tissue samples and their methylation was found to be closely associated with inactivation of gene expression. Further study will be required to elucidate the clinicopathological implications of these newly found DNA methylation markers in hepatocellular carcinoma.

AB - Promoter CpG island hypermethylation has become recognized as an important mechanism for inactivating tumor suppressor genes or tumor-related genes in human cancers of various tissues. Gene inactivation in association with promoter CpG island hypermethylation has been reported to be four times more frequent than genetic changes in human colorectal cancers. Hepatocellular carcinoma is also one of the human cancer types in which aberrant promoter CpG island hypermethylation is frequently found. However, the number of genes identified to date as hypermethylated for hepatocellular carcinoma (HCC) is fewer than that for colorectal cancer or gastric cancer, which can be attributed to fewer attempts to perform genome-wide methylation profiling for HCC. In the present study, we used bead-array technology and coupled methylation-specific PCR to identify new genes showing cancer-specific methylation in HCC. Twenty-four new genes have been identified as hypermethylated at their promoter CpG island loci in a cancer-specific manner. Of these, TNFRSF10C, HOXA9, NPY, and IRF5 were frequently hypermethylated in hepatocellular carcinoma tissue samples and their methylation was found to be closely associated with inactivation of gene expression. Further study will be required to elucidate the clinicopathological implications of these newly found DNA methylation markers in hepatocellular carcinoma.

KW - Bead array

KW - Carcinoma

KW - CpG Islands

KW - DNA methylation

KW - Hepatocellular

UR - http://www.scopus.com/inward/record.url?scp=77956607702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956607702&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.8.1152

DO - 10.3346/jkms.2010.25.8.1152

M3 - Article

C2 - 20676325

AN - SCOPUS:77956607702

VL - 25

SP - 1152

EP - 1159

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 8

ER -